{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T22:49:56Z","timestamp":1768690196106,"version":"3.49.0"},"reference-count":32,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2015,12,28]]},"abstract":"<jats:p>Silymarin and silybin are widely used for their hepatoprotective properties. Our previous studies confirm positive effect of silymarin on lipoprotein profile and lipid homeostasis. Advanced drug forms may improve the bioavailability of these compounds. In this study, we investigate the effects of silybin in different drug forms (standardized silybin, micronized silybin, and silybin in form of phytosomes) on dyslipidemia and glucose metabolism in hereditary hypertriglyceridemic (HHTg) rats. Male HHTg rats were divided into four groups of seven animals and were fed by experimental diets. Silybin significantly decreased serum level of triglycerides in groups of rats fed by standardized silybin and silybin in form of phytosomes compared to control group. Results show that silybin did not affect the total cholesterol level, but significantly increased the levels of HDL cholesterol in all groups of animals. Silybin in a standardized form had the highest hypotriglyceridemic effect. On the other hand, the micronized form has caused the highest increase of protective HDL and most significantly decreased glucose and insulin levels. Our results suggest that silybin is probably responsible for some positive properties of silymarin. Subsequent dose-dependent studies of silybin action may reveal the intensity of its positive effects on lipid and glucose parameters.<\/jats:p>","DOI":"10.33549\/physiolres.933235","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T10:14:34Z","timestamp":1587636874000},"page":"S507-S512","source":"Crossref","is-referenced-by-count":15,"title":["Positive Effects of Different Drug Forms of Silybin in the Treatment of Metabolic Syndrome"],"prefix":"10.33549","author":[{"given":"M.","family":"PORUBA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"MATU\u0160KOV\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"KAZDOV\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"OLIYARNYK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"MAL\u00cdNSK\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"TOZZI DI ANGELO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"VE\u010cE\u0158A","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine and Dentistry, Palack\u00fd University Olomouc, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2015,12,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"ALBERTI KG, ECKEL RH, GRUNDY SM, ZIMMET PZ, CLEEMAN JI, DONATO KA, FRUCHART JC, JAMES WP, LORIA CM, SMITH SC JR: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645, 2009.","DOI":"10.1161\/circulationaha.109.192644"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"BARTER PJ, PURANIK R, RYE KA: New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 9: 493-498, 2007.","DOI":"10.1007\/bf02938394"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"BROWN A, REYNOLDS LR, BRUEMMER D: Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 7: 369-375, 2010.","DOI":"10.1038\/nrcardio.2010.35"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"CALANI L, BRIGHENTI F, BRUNI R, DEL RIO D: Absorption and metabolism of milk thistle flavonolignans in humans. Phytomedicine 20: 40-46, 2012.","DOI":"10.1016\/j.phymed.2012.09.004"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"CULLEN P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cadiol 89: 943-949, 2000.","DOI":"10.1016\/S0002-9149(00)01127-9"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"ENJALBERT F, RAPIOR S, NOUGLIER-SOUL\u00c9 J, GUILLON S, AMOUROUX N, CABOT C: Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 40: 715-757, 2002.","DOI":"10.1081\/clt-120014646"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"FERENCI P, BEINHARDT S: Silibinin: an old drug in the high tech era of liver transplantation. J Hepatol 58: 409-411, 2013.","DOI":"10.1016\/j.jhep.2012.11.030"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"GALASSI A, REYNOLDS K, HE J: Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119: 812-819, 2006.","DOI":"10.1016\/j.amjmed.2006.02.031"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"GRUNDY SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83: 25F-29F, 1999.","DOI":"10.1016\/S0002-9149(99)00211-8"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"HUSEINI HF, LARIJANI B, HESHMAT R, FAKHRZADEH H, RADJABIPOUR B, TOLIAT T, RAZA M: The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 20: 1036-1039, 2006.","DOI":"10.1002\/ptr.1988"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"HUSSAIN SA: Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J Med Food 10: 543-547, 2007.","DOI":"10.1089\/jmf.2006.089"},{"key":"ref11","unstructured":"KIDD P, HEAD K: A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 10: 193-203, 2005."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"KLIMES I, VR\u00c1NA A, KUNES J, SEB\u00d6KOV\u00c1 E, DOBESOV\u00c1 Z, STOLBA P, ZICHA J: Hereditary hypertriglyceridemic rat: a new animal model of metabolic alterations in hypertension. Blood Press 4: 137-142, 1995.","DOI":"10.3109\/08037059509077585"},{"key":"ref13","unstructured":"MORAZZONI P, MONTALBETTI A, MALANDRINO S: Comparative biliary excretion of silybin after single oral doses of silipide and silymarin in rats. First Intl. Symposium on Natural Drugs and the Digestive Tract, Naples, Italy. Seattle, WA: Indena USA Inc.; www.indenausa.com, 1992."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"MORAZZONI P, MONTALBETTI A, MALANDRINO S, PIFFERI G: Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 18: 289-297, 1993.","DOI":"10.1007\/bf03188811"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"MOTTILLO S, FILION KB, GENEST J, JOSEPH L, PILOTE L, POIRIER P, RINFRET S, SCHIFFRIN EL, EISENBERG MJ: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56: 1113-1132, 2010.","DOI":"10.1016\/j.jacc.2010.05.034"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"NAVAB M, REDDY ST, VAN LENTEN BJ, FOGELMAN AM: HDL and cardiovascular disease: atherogenic and antheroprotective mechanisms. Nat Rev Cardiol 8: 222-232, 2011.","DOI":"10.1038\/nrcardio.2010.222"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"NORDESGAARD BG, BENN M, SCHNOHR P, TYBJAERG-HANSEN A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298: 299-308, 2007.","DOI":"10.1001\/jama.298.3.299"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"OROLIN J, VECERA R, JUNG D, MEYER UA, SKOTTOV\u00c1 N, ANZENBACHER P: Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha. Xenobiotica 37: 725-735, 2007.","DOI":"10.1080\/00498250701463333"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"PORUBA M, KAZDOV\u00c1 L, OLIYARNYK O, MALINSK\u00c1 H, MATUSKOV\u00c1 Z, TOZZI DI ANGELO I, SKOP V, VECERA R: Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome. Xenobiotica 45: 751-756, 2015.","DOI":"10.3109\/00498254.2015.1010633"},{"key":"ref20","unstructured":"SKOTTOV\u00c1 N, KRECMAN V: Silymarin as a potential hypocholesterolaemic drug. Physiol Res 47: 1-7, 1998."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"SKOTTOV\u00c1 N, VECERA R, URB\u00c1NEK K, V\u00c1NA P, WALTEROV\u00c1 D, CVAK L: Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharm Res 47: 17-26, 2003.","DOI":"10.1016\/s1043-6618(02)00252-9"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"SOBOLOV\u00c1 L, SKOTTOV\u00c1 N, VECERA R, URB\u00c1NEK K: Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats. Pharmacol Res 53: 104-112, 2006.","DOI":"10.1016\/j.phrs.2005.09.004"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"STOLBA P, DOBESOV\u00c1 Z, HUSEK P, OPLTOV\u00c1 H, ZICHA J, VR\u00c1NA A, KUNES J: The hypertriglyceridemic rat as a genetic model of hypertension and diabetes. Life Sci 51: 733-740, 1992.","DOI":"10.1016\/0024-3205(92)90482-5"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"SUKSOMBOON N, POOLSUP N, BOONKAEW S, SUTHISISANG CC: Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol 137: 1328-1333, 2011.","DOI":"10.1016\/j.jep.2011.07.059"},{"key":"ref25","unstructured":"VALENZULA A, GARRIDO A: Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 27: 105-112, 1994."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"VECERA R, ZACHAROV\u00c1 A, OROLIN J, SKOTTOV\u00c1 N, ANZENBACHER P: The effect of silymarin on expression of selected ABC transporters in the rat. Vet Med 56: 59-62, 2011.","DOI":"10.17221\/1579-vetmed"},{"key":"ref27","unstructured":"VR\u00c1NA A, KAZDOV\u00c1 L: The hereditary hypertriglyceridemic nonobese rat: an experimental model of human hypertriglyceridemia. Transplant Proc 22: 2579, 1990."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"VR\u00c1NA A, KAZDOV\u00c1 L, DOBESOVA Z, KUNES J, KREN V, B\u00cdL\u00c1 V, STOLBA P, KLIMES I: Triglyceridemia, glucoregulation, and blood pressure in various rat strains. Effects of dietary carbohydrates. Ann N Y Acad Sci 683: 57-68, 1993.","DOI":"10.1111\/j.1749-6632.1993.tb35692.x"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"WEBER C, NOELS H: Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17: 1410-1422, 2011.","DOI":"10.1038\/nm.2538"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"ZHANG S, ZHENG L, DONG D, WU L, YIN L, QI Y, HAN X, LIN Y, LIU K, PENG J: Effects of flavonoids from Rosa laevigata Michx fruit against high-fat diet-induced non-alcoholic fatty liver disease in rats. Food Chem 141: 2108-2116, 2013.","DOI":"10.1016\/j.foodchem.2013.05.019"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"ZICHA J, PECHANOV\u00c1 O, CAC\u00c1NYIOV\u00c1 S, CEBOV\u00c1 M, KRISTEK F, T\u00d6R\u00d6K J, SIMKO F, DOBESOV\u00c1 Z, KUNES J: Hereditary hypertriglyceridemic rat: a suitable model of cardiovascular disease and metabolic syndrome? Physiol Res 55 (Suppl 1): S49-S63, 2006.","DOI":"10.33549\/physiolres.930000.55.S1.49"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T03:35:56Z","timestamp":1666409756000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomed.cas.cz\/physiolres\/pdf\/64%20Suppl%204\/64_S507.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,12]]},"references-count":32,"URL":"https:\/\/doi.org\/10.33549\/physiolres.933235","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12,12]]}}}